The median diagnostic delay is almost 3.5 years in patients with sporadic hereditary transthyretin amyloidosis polyneuropathy (ATTR-PN).

Nipocalimab targets the Fc receptor to reduce pathogenic IgG levels and potentially prevent severe fetal anemia in HDFN and manage FNAIT. Nipocalimab shows promise as a transformative treatment for ...

Fetal MCA Doppler measurements that exceed 1.5 multiples of the mean suggest moderate-to-severe fetal anemia due to HDFN. Middle cerebral artery (MCA) peak systolic velocity (PSV) is a reliable ...

In their study, the investigators found that 8 of the 61 participants had 1 or more of the following conditions: AAV, non-AAV, autoimmunity, immunodeficiency, and malignancy. Follicular bronchiolitis ...

Clinicians must remain alert to the possibility of HDFN in pregnancy to ensure the best possible outcome. In a study published in the Asian Journal of Transfusion Science, Golia and colleagues sought ...

Diagnosing and treating MPO-ANCA-positive middle ear disease remains challenging, with mixed responses to steroid therapy. A retrospective review published in the Fukushima Journal of Medical Science ...

The prediction of those individuals at an increased risk for relapse remains a main unmet clinical need in the clinical management of AAV. Two novel antibodies—homeostatic iron regulator (HFE) and ...

Acute neuritis due to anti-myelin oligodendrocyte glycoprotein associated disease (MOGAD) improves without acute treatments, while myelitis due to MOGAD improves less if not treated, according to a ...

Mediation analysis showed that specific gut microbiota influenced ITP development through cytokine pathways. A recent investigation has provided important insights into the role of gut microbiota and ...

The management of neonatal neutropenia mostly encompasses close monitoring and supportive care. Neutropenia in neonates with hemolytic disease of the fetus and newborn (HDFN) is predominantly benign ...

For SLE-related GBS and CIDP, treatment for primary disease should also be initiated in addition to first-line therapy for GBS and CIDP. Systemic lupus erythematosus (SLE) may manifest as chronic ...

In patients with SCD, although the lifespan of their reticulocytes remains unknown, the number of immature reticulocytes is on the rise. Research has shown that reticulocytosis can predict morbidity ...